

EudraCT number	2022-000641-33
Sponsor Protocol Code	PAX
Title of Trial	Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study

SUMMARY ATTACHMENT

Quality of life and laboratory Endpoints

- **Neuropsychology assessment and quality of life:** No changes were observed in quality of life, cognitive performance, subjective everyday memory complaints, and anxiety and depression symptoms between the two groups during the study period.
- **Laboratory Outcomes:** The assessment of analytical parameters, encompassing inflammatory and biochemical markers, hematological indices, and coagulation parameters on days 8, 15, 22, 45, and 90, did not show any relevant differences between the TPE and Placebo groups. Inflammatory and coagulation parameters analysis (mean (s.d.)) between the two groups did not reveal any noteworthy differences